BVS Bioventus Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$11.88

Period return

+3.73 (+45.77%)

Volume

447.3K

2026-07-21O $11.4 H $11.91 L $11.4 C $11.88MA5 $11.98MA20 $11.04MA60 $10.03MA120 $9.45

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 04.Highin 14 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 22.LowBUY2 months ago
Barrington Research: Outperform
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 03. 07.LowBUY5 months ago
Barrington Research: Outperform
US analyst rating / recommendation change.
2026. 03. 07.LowBUY5 months ago
Craig-Hallum: Buy
US analyst rating / recommendation change.
2026. 02. 09.MediumBUY5 months ago
Barrington Research: Outperform
US analyst rating / recommendation change.
2025. 07. 08.MediumBUYlast year
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2025. 03. 29.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 18.LowBUYlast year
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2024. 12. 17.MediumHOLD2 years ago
JP Morgan: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $14.8 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 04.	After market close (AMC)	$0.22	—	—	$155.45M	—	Scheduled
FY2026 Q1	2025. 03. 29.	Time TBD	—	$-0.04	—	—	$123.88M	Reported
FY2025 Q3	2024. 09. 28.	Time TBD	—	$-0.56	—	—	$419.64M	Reported
FY2025 Q2	2024. 06. 29.	Time TBD	—	$-0.48	—	—	$280.67M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	259,060	$2.37M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	268,833	$2M	0.00%	—	New position

Bioventus Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 22.	Barrington Research	—	Maintain	Outperform → Outperform	—	Barrington Research: Outperform
2026. 03. 07.	Barrington Research	—	Maintain	Outperform → Outperform	—	Barrington Research: Outperform
2026. 03. 07.	Craig-Hallum	—	Maintain	Buy → Buy	—	Craig-Hallum: Buy
2026. 02. 09.	Barrington Research	—	Initiate coverage	— → Outperform	—	Barrington Research: Outperform
2025. 07. 08.	Cantor Fitzgerald	—	Initiate coverage	— → Overweight	—	Cantor Fitzgerald: Overweight
2025. 03. 18.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy